recently, the novel coronavirus pneumonia control system for the new crown pneumonia joint medical treatment team has issued the notice on strengthening the quality management of the new virus detection of the new samples. The notice pointed out that when sending the collected samples for nucleic acid detection, especially for the personnel of centralized isolation points and designated hospitals, the testing institutions should be strictly selected. The testing institution receiving the samples shall increase the frequency of spot check and carry out the external quality evaluation at least once a month. < / P > < p > < p > the notice pointed out that for key groups such as immigration personnel, the detection reagent with high sensitivity should be selected, and the extraction reagent and amplification instrument matched with the reverse transcription and amplification reagent should be selected for performance verification before being used in clinical detection. At least one weak positive and three negative internal quality control samples should be randomly put into each batch of testing to avoid false negative and false positive. < p > < p > < p > < p > the notice emphasizes that the quality assessment samples should be tested together with the real clinical samples. For laboratories with unqualified external quality assessment or inaccurate test results, nucleic acid testing business shall be suspended and rectification requirements shall be put forward within limited time; if the circumstances are serious, they shall be dealt with according to laws and regulations. National and provincial clinical laboratory centers should conduct post marketing evaluation on the detection reagents used in their jurisdiction, and guide local selection and procurement of reagents with high sensitivity and reliable quality. To encourage the clinical quality assessment of rapid testing equipment after marketing, so as to provide reference for testing institutions to select equipment.